Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by stockpatrolon Feb 07, 2023 4:44pm
162 Views
Post# 35272949

Algernon Pharmaceuticals is a company that is doing two impo

Algernon Pharmaceuticals is a company that is doing two impo
Algernon Pharmaceuticals is a company that is doing two important studies right now. One is a study to see if a drug called DMT is safe and works to treat stroke. The other study is to see if a drug called Ifenprodil works to treat chronic cough. They expect to get results from the first study in the third quarter of 2023 and start the second study in the same quarter. If the studies are successful, it could mean good things for the company and the treatments. Algernon Pharmaceuticals is currently trading at a low price compared to other similar companies.
 
https://www.reddit.com/r/PharmaStock/comments/10vixiu/algernon_pharmaceuticals_agnc_agnpf/
<< Previous
Bullboard Posts
Next >>